Barclays Adjusts Price Target on Amgen to $315 From $300, Maintains Equalweight Rating
DBS Maintains Amgen(AMGN.US) With Buy Rating
Amgen (AMGN) Rose Owing To The Announcement Of Promising Data For Its Novel Medication
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
U.S. Tweaks 2025 Medicare Price Negotiation Process
Amgen (NASDAQ:AMGN) Has A Somewhat Strained Balance Sheet
Eli Lilly and Co (LLY.US) explores new uses for 'weight-loss miracle drug' Zepbound, aiming to reduce the incidence of high-risk populations such as diabetes.
eli lilly and co is exploring new uses for its weight loss drug Zepbound to reduce the incidence of diabetes in high-risk populations, even if they are not overweight.
Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
Express News | La La Anthony Partners With Amgen to Share Candid, Behind-the-Scenes Look at How Plaque Psoriasis Affects Her Life
(AMGN) - Analyzing Amgen's Short Interest
Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report
Amgen Inc. (AMGN): Hedge Fund Interest and Strong Pipeline Support Moderate Buy Rating
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent Set to Advance in Top Drug Sales
Institutional Investors May Overlook Amgen Inc.'s (NASDAQ:AMGN) Recent US$7.9b Market Cap Drop as Long-term Gains Remain Positive
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
Notable Analyst Calls This Week: Microsoft, Starbucks and GM Among Top Picks
Federman & Sherwood Investigates Amgen, Inc. for Data Breach
Chevron, Visa Share Gains Contribute To Dow's Nearly 325-Point Climb
Cantor Highly Bullish on Amgen Obesity Drug, Starts Coverage at Overweight
Cantor Fitzgerald Initiates Amgen(AMGN.US) With Buy Rating, Announces Target Price $405